liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
A Randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Health Sciences, Pulmonary Medicine . Östergötlands Läns Landsting, Centre of Surgery and Oncology, Department of Respiratory Medicine UHL.
Show others and affiliations
2008 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 19, no 5, 939-945 p.Article in journal (Refereed) Published
Abstract [en]

 Background: This phase III randomized trial compared pemetrexed 500 mg/m2 (P500) with pemetrexed 900 mg/m2 (P900) to determine whether higher dosing benefits non-small-cell lung cancer (NSCLC) patients as second-line therapy. Patients and methods: Patients with locally advanced or metastatic NSCLC, previously treated with platinum-based chemotherapy, were randomly assigned to receive i.v. P500 or P900 every 3 week. Results: Accrual was terminated with 588/600 patients enrolled because an interim analysis indicated a low probability of improved survival and numerically greater toxicity on the P900 arm. P900 patients were permitted to continue treatment at P500. No statistical difference was observed between the treatment arms (P500 versus P900) for median survival {6.7 versus 6.9 months, hazard ratio [HR] = 1.0132 [95% confidence interval (CI) 0.837-1.226]}, progression-free survival [2.6 versus 2.8 months, HR = 0.9681 (95% CI 0.817-1.147)], or best overall tumor response [7.1% versus 4.3% (P = 0.1616)]. The incidence of drug-related grade 3/4 toxicity was typically <5% on both treatment arms, but was numerically higher on the P900 arm for most toxicity categories. Conclusions: P900 did not improve any efficacy measure over P500. P500 i.v. every 3 week remains the standard pemetrexed dose for second-line treatment of platinum-pretreated advanced NSCLC.

Place, publisher, year, edition, pages
2008. Vol. 19, no 5, 939-945 p.
Keyword [en]
advanced NSCLC, pemetrexed, second-line chemotherapy
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-42643DOI: 10.1093/annonc/mdm592Local ID: 67359OAI: diva2:263500
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2010-04-27

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Sörenson, Sverre
By organisation
Faculty of Health SciencesPulmonary Medicine Department of Respiratory Medicine UHL
In the same journal
Annals of Oncology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 43 hits
ReferencesLink to record
Permanent link

Direct link